Amicus Therapeutics
FOLD • NASDAQ
Amicus Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Bradley L. Campbell, with a market cap of $4.5B.
CEOBradley L. Campbell
Next Earnings
Upcoming earnings announcement for Amicus Therapeutics
Date
Thursday, April 30, 2026 (in 4 weeks)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.08
Revenue Estimate
$164.6M
Earnings History
Past 12 earnings reports for Amicus Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | Q4 2025 | $0.10Est: $0.14 | -28.6% | $185.2MEst: $183.0M | +1.2% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.17Est: $0.09 | +88.9% | $169.1MEst: $165.3M | +2.3% | 10-Q |
| Jul 31, 2025 | Q2 2025 | $0.01Est: -$0.01 | +200.0% | $154.7MEst: $147.0M | +5.2% | 10-Q |
| May 1, 2025 | Q1 2025 | $0.03Est: $0.08 | -62.5% | $125.2MEst: $136.4M | -8.2% | 10-Q |
| Feb 19, 2025 | Q4 2024 | $0.09Est: $0.09 | 0.0% | $149.7MEst: $147.9M | +1.2% | 10-K |
| Nov 6, 2024 | Q3 2024 | $0.10Est: $0.00 | — | $141.5MEst: $135.3M | +4.6% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $0.06Est: -$0.05 | +220.0% | $126.7MEst: $121.4M | +4.3% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.02Est: -$0.07 | +71.4% | $110.4MEst: $111.2M | -0.7% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.01Est: -$0.06 | +116.7% | $115.1MEst: $114.3M | +0.7% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.07Est: -$0.08 | +12.5% | $103.5MEst: $101.4M | +2.1% | — |
| Aug 8, 2023 | Q2 2023 | -$0.15Est: -$0.12 | -25.0% | $94.5MEst: $89.9M | +5.2% | 10-Q |
| May 10, 2023 | Q1 2023 | -$0.18Est: -$0.15 | -20.0% | $86.3MEst: $83.1M | +3.8% | — |